Welcome to our dedicated page for Dariohealth SEC filings (Ticker: DRIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings for DarioHealth Corp are anything but routine. A single 10-K can weave together FDA pathways, digital therapeutics algorithms, and multi-year clinical data—details essential to gauging how its chronic-condition platform turns R&D into recurring revenue. If you’ve ever opened a filing looking for patent amortization or payer adoption metrics, you know the frustration. Stock Titan solves that pain.
Our AI breaks down DarioHealth Corp annual report 10-K simplified, highlights segment revenue from employer contracts, and flags capitalized software costs in minutes. The same engine delivers bullet-proof context for each DarioHealth Corp quarterly earnings report 10-Q filing and pushes alerts for every DarioHealth Corp 8-K material events explained. Need to track DarioHealth Corp insider trading Form 4 transactions? We stream DarioHealth Corp Form 4 insider transactions real-time, mapping each executive move to option grant dates and clinical milestones. Questions like “How is share-based compensation trending?” or “Did management sell stock before a material announcement?” are answered instantly.
Whether you’re understanding DarioHealth Corp SEC documents with AI for diligence or performing a DarioHealth Corp earnings report filing analysis, the platform connects forms to real-world drivers:
- DarioHealth Corp executive stock transactions Form 4 reveal insider confidence as new condition modules launch.
- DarioHealth Corp proxy statement executive compensation links pay structures to clinical outcome targets.
- 10-Qs trace membership growth across diabetes, hypertension, and behavioral health programs.
Skip the 300-page PDFs. Stock Titan delivers concise, expert narratives, real-time updates, and the clarity investors need to act.
DarioHealth Corp. insider transaction summary The reporting person, Dennis M. McGrath, a company director, received a restricted share award of 20,000 shares of DarioHealth common stock on 09/11/2025 that vests on the last day of the second anniversary of the grant date. Following the award and a prior corporate action, Mr. McGrath is shown as beneficially owning 27,737 shares, an amount that reflects a 20-for-1 reverse stock split effected on 08/28/2025. The transaction is recorded as an acquisition with a reported price of $0 for the restricted shares.
DarioHealth Corp. director Dennis Matheis reported a non‑derivative acquisition of company stock. On 09/11/2025 Mr. Matheis received a restricted share award of 20,000 shares at a reported price of $0. The award is scheduled to vest on the last day of the second anniversary after the grant date. Following the reported transaction, Mr. Matheis beneficially owned 27,631 shares, an amount that reflects a 20‑for‑1 reverse stock split effected on August 28, 2025. The Form 4 was signed on 09/15/2025.
Steven Nelson, President and CCO of DarioHealth Corp. (DRIO), reported an open-market purchase of common stock on 08/27/2025. The Form 4 shows a purchase of 40,000 shares at $0.53 per share, bringing his reported beneficial ownership to 95,000 shares. The filing identifies Nelson as a director and officer and is signed by him on 08/27/2025.
DarioHealth Corp. filed an 8-K dated
DarioHealth Corp. reporting persons Nantahala Capital Management, LLC and principals Wilmot B. Harkey and Daniel Mack disclose beneficial ownership of 4,690,019 shares, representing 9.99% of the outstanding common stock as of June 30, 2025. The disclosed position includes 2,997,716 shares that may be acquired within 60 days through the exercise of warrants, and all voting and dispositive power is reported as shared rather than sole. Nantahala identifies two advised funds with rights to receive proceeds or dividends from more than 5% of the shares reported.
DarioHealth Corp. reported total revenues of $5.369 million for the quarter ended June 30, 2025, split between Services $3.661M and Consumer hardware $1.708M. Gross profit was $2.964M for the quarter and $6.846M for the six months, while operating expenses were $12.164M for the quarter, producing an operating loss of $9.200M. The company recorded a net loss of $12.990M for the quarter and $22.217M for the six months; basic and diluted loss per share was $0.18 for the quarter and $0.33 for six months.
On the balance sheet, cash and cash equivalents were $21.954M (down from $27.764M at year-end), total assets were $108.325M, and accumulated deficit totaled $422.971M. The company refinanced with a $32.5M Callodine credit agreement on April 30, 2025, but did not meet one covenant as of June 30, 2025; Callodine waived the default conditional on a successful equity cure by November 15, 2025. Management discloses that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from issuance.
FAQ
What is the current stock price of Dariohealth (DRIO)?
What is the market cap of Dariohealth (DRIO)?
